<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102575">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01987960</url>
  </required_header>
  <id_info>
    <org_study_id>14865A</org_study_id>
    <secondary_id>2012-004982-41</secondary_id>
    <nct_id>NCT01987960</nct_id>
  </id_info>
  <brief_title>Brexpiprazole as an Additional Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD)</brief_title>
  <official_title>Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose Study of Brexpiprazole as Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of brexpiprazole as adjunctive treatment to paroxetine or
      sertraline on PTSD symptoms.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from randomisation in PTSD symptoms using CAPS-2 total score</measure>
    <time_frame>Baseline and Week 28</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinician-Administered PTSD Scale Part 2 (CAPS-2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from randomisation in global clinical impression using CGI-S score</measure>
    <time_frame>Baseline and Week 28</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical Global Impression - Severity of Illness (CGI-S)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from randomisation in functioning using SDS score</measure>
    <time_frame>Baseline and Week 28</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sheehan Disability Scale (SDS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Up to 28 weeks and a 30-day telephone contact or clinic visit</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>Up to 28 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of withdrawals</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">592</enrollment>
  <condition>Post-traumatic Stress Disorder</condition>
  <condition>PTSD</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo adjunct to open-label treatment with a commercially available approved treatment for PTSD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brexpiprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brexpiprazole adjunct to open-label treatment with a commercially available approved treatment for PTSD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Once daily, tablets, orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brexpiprazole</intervention_name>
    <description>Up to 3 mg/day, once daily dose, tablets, orally</description>
    <arm_group_label>Brexpiprazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient has PTSD, diagnosed according to DSM-IV-TRâ„¢ and confirmed by the Mini
             International Neuropsychiatric Interview (MINI).

          -  The patient has a pre-defined Clinician-Administered PTSD Scale Part 2 (CAPS-2) total
             score at Screening and Baseline Visits.

          -  The reported duration of the PTSD is at least 3 months.

        Exclusion Criteria:

          -  The index traumatic event that led to development of PTSD took place more than 15
             years before screening.

          -  The patient has a severe personality disorder that in the investigator's opinion may
             interfere with the conduct of the study.

          -  The patient is at significant suicidal risk.

        Other inclusion and exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@lundbeck.com</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <email>LundbeckClinicalTrials@lundbeck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>US005</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 13, 2013</lastchanged_date>
  <firstreceived_date>November 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress, Psychological</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paroxetine</mesh_term>
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
